nucleus accumbens, etc.), which is implicated in euphoria and repeated substance use [9,10,11]
In addition to weight reduction, treatment with mazdutide was associated with significant improvements in metabolic parameters, including reductions in glycated hemoglobin (HbA1c), fasting plasma glucose, blood pressure, and lipid profiles in individuals with type 2 diabetes mellitus
Drucker highlighted the SELECT trial, which demonstrated a 25% reduction in heart attacks and a 19% reduction in all-cause mortality among participants receiving the medication
GLP-1/GIP medications have strong clinical trial evidence for average weight loss and are FDA-approved for chronic weight management under specific criteria, while lipotropic injections have limited evidence as a weight-loss treatment
Evernorth Health Services recently launched Evernorth EnGuide SM Pharmacy, a new pharmacy focused solely on GLP-1 home delivery to meet the growing need and demand for these critical medications